Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Plos One|November 5, 2020
Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participantsFrederick K Ho, Fanny Petermann-Rocha, Stuart R Gray, et al.
BMC Medicine|November 10, 2020
Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK BiobankFanny Petermann-Rocha, Peter Hanlon, Stuart R Gray, et al.
The Lancet Regional Health. Europe|December 27, 2024
Maternal and pregnancy factors contributing to the association between area deprivation and infant mortality in England: a retrospective cohort studyFrederick K Ho, Max Allan, Hui Shao, et al.
Eclinicalmedicine|July 16, 2024
Evidence for exercise-based interventions across 45 different long-term conditions: an overview of systematic reviewsGrace O Dibben, Lucy Gardiner, Hannah M L Young, et al.
BMC Medicine|January 8, 2025
Multimorbidity clusters and their associations with health-related quality of life in two UK cohortsLewis Steell, Stefanie J Krauth, Sayem Ahmed, et al.
Journal of Multimorbidity and Comorbidity|September 22, 2025
Co-design and development of a Personalised Exercise-based Rehabilitation and self-management programme FOR people with Multiple long-term conditions: The PERFORM interventionPaulina Daw, Colin J Greaves, Nikki Gardiner, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
Nature|October 20, 2006
Corneal avascularity is due to soluble VEGF receptor-1Balamurali K Ambati, Miho Nozaki, Nirbhai Singh, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Pageof 9